BDR Pharma takes over stake in Acme Formulation drug business

BDR Pharma is buying a controlling stake in the oral solid formulations business of Acme Formulation and its subsidiaries. The deal involves taking over from current shareholders, who are led by the investment firm PAG. The entire transaction values the business at 250 million dollars. BDR Pharma stated that the purchase brings in new product lines for thyroids, female sex hormones, and general medicines. These additions fit well with the company's current focus on cancer care, critical care, and women's health, and will help the firm reach more international markets. Dharmesh Shah, who is the Chairman and Managing Director of BDR Pharma, noted that the deal strengthens their contract manufacturing setup and supports their wider global expansion plans. After this sale goes through, PAG and Viral Shah will still own all of Immacule, which handles sterile injectable contract manufacturing and recently opened a new plant that can make 200 million units. Viral Shah, who founded Acme and serves as Immacule's Managing Director, added that BDR Pharma's expertise in complex medicines will benefit their manufacturing clients around the world.

Context

Contract manufacturing organizations help pharmaceutical companies produce medicines on a large scale without needing to build extra factories. Mergers and acquisitions like this are common in the healthcare sector as firms look to add specialized product lines and expand their reach into global markets.